Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931163 · ClinicalTrials.gov registry record · Phase 2
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
A Phase 2 study, sponsored by Jenny C. Chang, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01931163 is a Phase 2 study that has completed, run by Jenny C. Chang, MD. The registered enrollment target is 24 participants.
The verdict
NCT01931163, a Phase 2 study, has completed, sponsored by Jenny C. Chang, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy with Everolimus is in treating subjects with triple negative breast cancer who have residual disease after chemotherapy.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931163
The ClinicalTrials.gov registry entry for NCT01931163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jenny C. Chang, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT01931163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931163 about?
NCT01931163 is a clinical study titled "NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer". RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: The purpose of this study is to test how effective combining Cisplatin chemotherapy with Everolimus is in treating subject...
What is the current status of trial NCT01931163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-07. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01931163?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT01931163?
This trial is sponsored by Jenny C. Chang, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.